Navidea Biopharmaceuticals Inc (NAVB)

Oncology Corporate Profile

HQ Location

5600 Blazer Parkway, Suite 200
Dublin, OH 43017

Company Description

Navidea Biopharmaceuticals is a global leader in precision diagnostics which pinpoint molecular sites and pathways to identify the presence and status of disease. Through our innovative and flexible platforms and products, we are committed to improving diagnostic accuracy, empowering clinical decision-making and enhancing patient care. The Company focuses on the development and commercialization of innovative precision diagnostic agents that can and will make a difference for individuals – and families, physicians and care givers – touched by devastating conditions like cancer, dementia and movement disorders.

Website: http://navidea.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
NAV-1800monoclonal antibodyColorectal cancerI

View additional information on product candidates here »

Pipeline image

Source


http://navidea.com/

Recent News Headlines

Navidea Completes Sale of North American Rights of Lymphoseek® to Cardinal Health

3/3/2017 08:01 pm

[Business Wire] - Navidea Biopharmaceuticals announced today the completion of the sale to Cardinal Health of its Lymphoseek® product for lymphatic mapping, lymph node biopsy and the diagnosis of metastatic spread to lymph nodes for the staging of cancer in North America.

Navidea to Hold Conference Call to Provide Investor Update on Status of Ongoing Corporate Events

1/27/2017 09:05 pm

[Business Wire] - Navidea Biopharmaceuticals, Inc. today announced that management will hold an audio webcast conference call on Tuesday, January 31, 2017 at 4:30 p.m. to provide investor update on status of ongoing corporate events.

Navidea to Present at Upcoming Investor Conference

1/6/2017 09:02 pm

[at noodls] - DUBLIN, Ohio--(BUSINESS WIRE)--Jan. 6, 2017-- Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) today announced that management will present at an upcoming investor conference. An audio webcast of the presentation ...

Navidea to Present at Upcoming Investor Conference

1/6/2017 09:01 pm

[Business Wire] - Navidea Biopharmaceuticals, Inc. today announced that management will present at an upcoming investor conference. An audio webcast of the presentation will be available live at the URL links noted below.

Navidea Signs Asset Purchase Agreement with Cardinal Health

11/23/2016 10:03 pm

[at noodls] - DUBLIN, Ohio--(BUSINESS WIRE)--Nov. 23, 2016-- Navidea Biopharmaceuticals (NYSE MKT: NAVB) today announced that it has entered into a definitive asset purchase agreement with Cardinal Health (NYSE: CAH). ...

Navidea Signs Asset Purchase Agreement with Cardinal Health

11/23/2016 08:01 pm

[Business Wire] - Navidea Biopharmaceuticals today announced that it has entered into a definitive asset purchase agreement with Cardinal Health . Pursuant to the purchase agreement, Cardinal Health will purchase Navidea’s Lymphoseek® product for lymphatic mapping, lymph node biopsy and the diagnosis of metastatic spread to lymph nodes for the staging of cancer in North America.